Carglumic acid

Carglumic acid
Clinical data
Trade names	Carbaglu, Ucedane
Other names	(S)-2-ureidopentanedioic acid
AHFS/Drugs.com	Monograph
License data	US DailyMed: Carglumic acid;
Pregnancy; category	AU: B1;
Routes of; administration	By mouth
ATC code	A16AA05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	30%
Protein binding	Undetermined
Metabolism	Partial
Elimination half-life	4.3 to 9.5 hours
Excretion	Fecal (60%) and kidney (9%, unchanged)
Identifiers
	IUPAC name (2S)-2-(carbamoylamino)pentanedioic acid;
CAS Number	1188-38-1 ;
PubChem CID	121396;
IUPHAR/BPS	7458;
DrugBank	DB06775 ;
ChemSpider	1265942 ; 108351 ;
UNII	5L0HB4V1EW;
KEGG	D07130 ;
ChEBI	CHEBI:71028 ;
ChEMBL	ChEMBL1201780 ;
CompTox Dashboard (EPA)	DTXSID7046706 ;
ECHA InfoCard	100.116.323
Chemical and physical data
Formula	C6H10N2O5
Molar mass	190.155 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C(CC(=O)O)[C@@H](C(=O)O)NC(=O)N;
	InChI InChI=1S/C6H10N2O5/c7-6(13)8-3(5(11)12)1-2-4(9)10/h3H,1-2H2,(H,9,10)(H,11,12)(H3,7,8,13)/t3-/m0/s1 ; Key:LCQLHJZYVOQKHU-VKHMYHEASA-N ;
	(what is this?) (verify)

Carglumic acid, sold under the brand name Carbaglu among others, is used for the treatment of hyperammonaemia. Carglumic acid is a carbamoyl phosphate synthetase 1 (CPS 1) activator.

The most common adverse effects include vomiting, abdominal pain, pyrexia (fever), and tonsillitis, anemia, diarrhea, ear infection, other infections, nasopharyngitis, decreased hemoglobin levels, and headache.

It was approved for medical use in the United States in March 2010. Carglumic acid is an orphan drug. It is available as a generic medication.